|
Dr. Martin has 20 years of experience in biomedical research and medical device development, specializing in novel applications of high technology materials for vascular and cardiovascular disease treatment. He was recruited to lead NovoStent to recreate his past successes of technology, product and business development in the cardiovascular implant industry. G.Ray brings a winning record of establishing strategic partner relationships, fundraising, and directing new business initiatives.
Prior to joining NovoStent, G. Ray was a Vice President of Business Development at Boston Scientific, as well as TriVascular, which was acquired by Boston Scientific. Before joining TriVascular, G. Ray held executive positions at C.R. Bard and W. L. Gore where he led the development of various stent graft applications. From inventing to management of mature enterprises, his leadership has resulted in the development of several businesses and products dedicated to minimally invasive treatment of vascular disorders.
G.Ray is a Summa Cum Laude graduate of West Virginia University where he received a B.S. in Chemical Engineering, and he holds a PhD in Chemical Engineering and Bioengineering from Carnegie Mellon University. G.Ray has expertise in developing biomaterials to mimic various human vessels, and his technical contributions are recognized in numerous peer-reviewed publications and patents. | 